Jorveza (
generic name: budesonide is a corticosteroid with anti-inflammatory properties. It is specifically
designed to treat eosinophilic esophagitis (EoE), also known as
inflammation of the esophagus, in adults. Budesonide binds to glucocorticoid receptors, reducing the release of substances that cause inflammation. This action
helps to alleviate the chronic inflammation characteristic of EoE, improving symptoms such as difficulty swallowing and food impaction. The dissolving nature of Jorveza ensures direct delivery of the medication to the esophageal mucosa, which is essential for effective treatment.
Dosage
For remission induction in adults, the recommended dosage is one tablet taken twice daily, morning and evening, after meals. The typical duration of this induction treatment is six weeks. If symptoms persist, the treatment may be extended up to 12 weeks. To maintain remission, a dosage of either 0.5 mg or 1 mg taken twice daily is usually advised, depending on the patient’s clinical need based on individual response and disease severity.
Follow the printed instructions on the Patient Information leaflet. Jorveza tablets should be taken immediately after removal from the blister pack. Place the tablet on the tip of the tongue and press it gently against the roof of the mouth, allowing it to dissolve completely without chewing or swallowing it whole. This process typically takes 2 to 5 minutes but may take longer in some cases. During this time, avoid eating, drinking, brushing teeth, or using mouthwash for at least 30 minutes to ensure optimal efficacy.
Storage
Store Jorveza tablets in their original packaging to protect them from
light and moisture. Keep the medication at room temperature, below 25°C (77°F), and out of reach of children.
Common Questions About Jorveza
How does Jorveza differ from other budesonide formulations?
Jorveza is specifically formulated to dissolve in the mouth, allowing direct delivery of budesonide to the esophageal lining. This targeted approach is particularly effective for treating eosinophilic esophagitis, as it ensures the medication directly contacts the affected area. Other budesonide formulations, such as inhalers or standard tablets, are designed for different conditions and may not provide the same localized effect in the esophagus.
Can Jorveza be used in pediatric patients?
Jorveza is currently approved for use in adults aged 18 and over. The safety and efficacy of Jorveza in pediatric patients have not been established, and therefore, its use in individuals under 18 years of age is not recommended.
Are there any dietary restrictions while taking Jorveza?
While taking Jorveza, it is advisable to avoid consuming grapefruit or grapefruit juice, as they can interfere with the metabolism of budesonide, potentially leading to increased side effects.
This text is for informational purposes only. Please consult a doctor or pharmacist before using any medication.Â
Read the information leaflet that comes with the medication.
If a sudden allergic reaction (anaphylaxis) occurs after taking Jorveza, with symptoms like swelling of the face, tongue, or throat making it difficult to breathe or swallow, or there is wheezing, hives, rash, blistering, or peeling of the skin, call a doctor or 911 right away, or go to an emergency room immediately.
Most people who use Jorveza do not experience any adverse side effects. Doctors prescribe this medication because they assess the benefits of such treatment outweigh any likely unwanted effects.
Some of the side effects that have been reported include:
- Oral candidiasis (thrush): Fungal infections in the mouth or throat, presenting as white patches or soreness.
- Headache: Mild to moderate headaches during treatment.
- Nausea: Feeling of discomfort in the stomach with an urge to vomit.
- Abdominal pain: Discomfort or pain in the stomach area.
Warnings
Consult a healthcare provider before using Jorveza during pregnancy or while breastfeeding, as budesonide may pass into breast milk.
Not all side effects are listed here. If these or other unlisted symptoms persist or worsen, consult a healthcare provider or pharmacist.
Jorveza is prescribed for the treatment of eosinophilic esophagitis (EoE), a chronic immune-mediated condition characterized by inflammation of the esophagus. EoE occurs when eosinophils, a type of white blood cell, accumulate in the esophageal tissue, leading to symptoms such as difficulty swallowing (dysphagia), food impaction, chest pain, and heartburn. If left untreated, EoE can result in esophageal narrowing and strictures, further complicating swallowing. The exact cause of EoE is not fully understood, but it is often associated with allergic responses to certain foods or environmental allergens.
Common symptoms of EoE include:
- Dysphagia: Difficulty swallowing solid foods, which may progressively worsen.
- Food impaction: Food becoming lodged in the esophagus, sometimes requiring emergency medical intervention.
- Chest pain: Non-cardiac chest pain that can mimic heartburn.
- Heartburn: Persistent acid reflux that does not respond well to standard antacid treatments.
Early diagnosis and treatment are crucial to prevent complications such as esophageal strictures.